drugset / Trial / NCT06872125
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Timeline
- Start
- 2025-06-04
- Primary completion
- 2027-03
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zorevunersen | Antisense oligonucleotide | 45 mg | Intrathecal |